secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K/A
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001628280-25-001065
Event type: m_and_a
Sentiment:  negative
Materiality: 1.00
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell closes ImmPACT Bio acquisition; acquired firm had $136.8M deficit, going concern flag
--------------------------------------------------------------------------------

- ImmPACT Bio's audited FY2023 net loss $58.9M, R&D spend $44.0M, accumulated deficit $136.8M.
- Auditors express substantial doubt about ImmPACT's ability to continue as a going concern due to recurring losses and negative cash flows.
- ImmPACT had $39.9M cash and equivalents, $1.2M short-term investments, $5.9M property/equipment as of Dec 31, 2023.
- Lyell completed acquisition of ImmPACT on Oct 31, 2024; combined pro forma financials filed for FY2023 and nine months ended Sep 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828025001065/0001628280-25-001065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828025001065/lyel-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-001065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer